Does Treatment Adherence Therapy reduce expense of healthcare use in patients with psychotic disorders? Cost-minimization analysis in a randomized controlled trial

Schizophrenia Research

Volumn 133, Issue 1-3, 2011, Pages 47-53

  Gilden, J ^a   Staring, A B P ^a,b   der Gaag, M van ^c,d   Mulder, C L ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BAVO Europoort   (Netherlands)

^c PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adherence; Compliance; Cost minimization analysis; Psychosis; Schizophrenia

Indexed keywords

ADULT; ARTICLE; BEHAVIOR THERAPY; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; LEGAL ASPECT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIC NURSING; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT ADHERENCE THERAPY; TREATMENT OUTCOME;

ADULT; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY;

EID: 81955161943     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.09.025     Document Type: Article

References (28)

1. Andersen L.P., Mikkelsen K.L. Recall of occupational injuries: a comparison of questionnaire and diary data. Saf. Sci. 2008, 46(2):255-260.
2. Ascher-Svanum H., Zhu B., Faries D.E., Furiak N.M., Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res. Notes 2009, 2:6.
3. Ascher-Svanum H., Zhu B., Faries D.E., Salkever D., Slade E.P., Peng X., Conley R.R. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2.
4. Custodial Institutions Agency [Dienst Justitiële Inrichtingen] Yearmessage 2008, Step in the Right Direction 2008, Ministry of Justice, Netherlands.
5. Damen J., Thuresson P.O., Heeg B., Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl. Health Econ. Health Policy 2008, 6(4):189-197.
6. Deuning C.M., Zwakhals S.L.N., Verkleij H. Average distance of every inhabitant in the Netherlands to the closest healthcare facility of a specific kind. Dutch health care performance report 2008. Bilthoven: RIVM http://www.gezondheidszorgbalans.nl/toegankelijkheid/geografische-toegankelijkheid/.
7. Dijkgraaf M.G., Van der Zanden B.P., De Borgie C.A., Blanken P., Van Ree J.M., Van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ 2005, 330(7503):1297.
8. Dolder C.R., Lacro J.P., Leckband S., Jeste D.V. Interventions to improve antipsychotic medication adherence: review of recent literature. J. Clin. Psychopharmacol. 2003, 23(4):389-399.
9. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press. third ed.
10. Gibson P.J., Damler R., Jackson E.A., Wilder T., Ramsey J.L. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 2004, 7(1):22-35.
11. Gray R., Wykes T., Gournay K. From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J. Psychiatr. Ment. Health Nurs. 2002, 9(3):277-284.
12. Hakkaart-Van Roijen L., Van Straten A., Donker M., Tiemens B. Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P) 2002, Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam.
13. Kemp R., Hayward P., Applewhaite G., Everitt B., David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996, 312(7027):345-349.
14. Kemp R., Kirov G., Everitt B., Hayward P., David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br. J. Psychiatry 1998, 172:413-419.
15. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63(10):892-909.
16. Marcus S.C., Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr. Bull. 2008, 34(1):173-180.
17. Marks I.M., Connolly J., Muijen M., Audini B., McNamee G., Lawrence R.E. Home-based versus hospital-based care for people with serious mental illness. Br. J. Psychiatry 1994, 165(2):179-194.
18. Masand P.S., Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr. Clin. Pharmacol. 2006, 1(1):47-56.
19. Oostenbrink J.B., Bouwmans C.A.M., Koopmanschap M.A., Rutten F.F.H. Manual for Cost Research. Methods and Standardised Cost Prices For Economic Evaluations In Healthcare. Updated Version 2004 2004, Institute for Medical Technology Assessment, Erasmus MC, by order of the health care insurance board.
20. Roberts R.O., Bergstralh E.J., Schmidt L., Jacobsen S.J. Comparison of self-reported and medical record health care utilization measures. J. Clin. Epidemiol. 1996, 49(9):989-995.
21. Staring A.B.P., Mulder C.L., Van der Gaag M., Selten J.P., Loonen A.J.M., Hengeveld M.W. Understanding and improving treatment adherence in patients with psychotic disorders: a review and a proposed intervention. Curr. Psychiatry Rev. 2006, 2(4):1-8.
22. Staring A.B.P., Van der Gaag M., Koopmans G.T., Selten J.P., Van Beveren J.M., Hengeveld M.W., Loonen A.J.M., Mulder C.L. Treatment Adherence Therapy in patients with psychotic disorders: randomized controlled trial. Br. J. Psychiatry 2010, 197:1-8.
23. Statistics Netherlands [Centraal Bureau voor de Statistiek] Consumer prices; inflation as of 1963 http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLNL&PA=70936NED&D1=0&D2=532,545,558,571,584,597&HD=100729-0921&HDR=T&STB=G1.
24. Sun S.X., Liu G.G., Christensen D.B., Fu A.Z. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr. Med. Res. Opin. 2007, 23(10):2305-2312.
25. Tait L., Birchwood M., Trower P. A new scale (SES) to measure engagement with community mental health services. J. Ment. Health 2002, 11:191-198.
26. The health care insurance board [College voor zorgverzekeringen] Healthnumbersdata 2008 http://www.zorgcijfersdata.cvz.nl.
27. Zhu B., Ascher-Svanum H., Faries D.E., Peng X., Salkever D., Slade E.P. Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry 2008, 8:72.
28. Zygmunt A., Olfson M., Boyer C.A., Mechanic D. Interventions to improve medication adherence in schizophrenia. Am. J. Psychiatry 2002, 159(10):1653-1664.